These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 21677600

  • 1. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S, Ueland T, Wennerblom B, Sigurdadottir V, Eiskjær H, Bøtker HE, Ekmehag B, Jansson K, Mortensen SA, Saunamaki K, Simonsen S, Gude E, Bendz B, Solbu D, Aukrust P, Gullestad L.
    Transplantation; 2011 Jul 27; 92(2):235-43. PubMed ID: 21677600
    [Abstract] [Full Text] [Related]

  • 2. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ, A2310 IVUS Substudy Investigators.
    JACC Heart Fail; 2013 Oct 27; 1(5):389-99. PubMed ID: 24621971
    [Abstract] [Full Text] [Related]

  • 3. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
    Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Sigurdardottir V, Dellgren G, Erikstad I, Solberg OG, Ueland T, Aukrust P, Gullestad L, SCHEDULE (SCandinavian HEart transplant everolimus De novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators.
    Am J Transplant; 2015 Jul 27; 15(7):1967-75. PubMed ID: 25783974
    [Abstract] [Full Text] [Related]

  • 4. Suppressive effects of conversion from mycophenolate mofetil to everolimus for the development of cardiac allograft vasculopathy in maintenance of heart transplant recipients.
    Watanabe T, Seguchi O, Nishimura K, Fujita T, Murata Y, Yanase M, Sato T, Sunami H, Nakajima S, Hisamatsu E, Sato T, Kuroda K, Hieda M, Wada K, Hata H, Ishibashi-Ueda H, Miyamoto Y, Fukushima N, Kobayashi J, Nakatani T.
    Int J Cardiol; 2016 Jan 15; 203():307-14. PubMed ID: 26523360
    [Abstract] [Full Text] [Related]

  • 5. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskjær H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Dellgren G, Ueland T, Aukrust P, Gullestad L, SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators.
    Circ Heart Fail; 2018 Sep 15; 11(9):e004050. PubMed ID: 30354362
    [Abstract] [Full Text] [Related]

  • 6. Everolimus for cardiac allograft vasculopathy--every patient, at any time?
    Patel JK, Kobashigawa JA.
    Transplantation; 2011 Jul 27; 92(2):127-8. PubMed ID: 21555972
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.
    Valantine H.
    J Heart Lung Transplant; 2005 Apr 27; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
    Groetzner J, Kaczmarek I, Schulz U, Stegemann E, Kaiser K, Wittwer T, Schirmer J, Voss M, Strauch J, Wahlers T, Sohn HY, Wagner F, Tenderich G, Stempfle HU, Mueller-Ehmsen J, Schmid C, Vogeser M, Koch KC, Reichenspurner H, Daebritz S, Meiser B, Reichart B, VENINAHTx-Investigators.
    Transplantation; 2009 Mar 15; 87(5):726-33. PubMed ID: 19295318
    [Abstract] [Full Text] [Related]

  • 13. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
    Eisen H.
    Nephrol Dial Transplant; 2006 Jul 15; 21 Suppl 3():iii9-13. PubMed ID: 16815858
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation.
    Mirza K, Gustafsson F, Gullestad L, Arora S, Andersen C.
    Transpl Immunol; 2016 Sep 15; 38():75-7. PubMed ID: 27260644
    [Abstract] [Full Text] [Related]

  • 18. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil.
    Kaczmarek I, Ertl B, Schmauss D, Sadoni S, Knez A, Daebritz S, Meiser B, Reichart B.
    J Heart Lung Transplant; 2006 May 15; 25(5):550-6. PubMed ID: 16678034
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.